花旗：维持锦欣生殖(01951)“买入”评级 目标价下调至6港元
花旗发布报告称，维持锦欣生殖(01951)“买入”评级，考虑到深圳新院区延迟开业及武汉医院的利润，将2024及2025年收入下调10%和16.8%，每股盈测下调37.7%及40.9%，目标价由11.5港元下调至6港元。该行认为其估值仍然具有吸引力。同时，先前的医疗事故和诉讼造成的业务中断已经解决，预计集团的业务将会逐步恢复。
报告中称，锦欣生殖去年收入同比增18%至27.89亿元人民币，净利润升1.94倍至3.47亿元人民币，经调整净利润增72%至4.72亿元人民币，表现符合盈警预告。随着疫情和成本控制后业务复苏，公司毛利率从2022财年的37%扩大至42.1%。销售及行政支出比率降至24.1%；净利润率为12.4%。管理层给予指引2024财年的经调整净利润将同比升15%。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.